RecruitingPhase 2Phase 3NCT04356664

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study


Sponsor

Hopital Foch

Enrollment

180 participants

Start Date

Mar 18, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 36 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GnRH agonist for people with adenomyosis, endometriosis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 36 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGnRH agonist

One or two intramuscular injections of Decapeptyl 3 mg


Locations(1)

Hopital Foch

Suresnes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04356664


Related Trials